{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T04:38:05Z","timestamp":1768451885049,"version":"3.49.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2012,6,22]],"date-time":"2012-06-22T00:00:00Z","timestamp":1340323200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1007\/s11033-012-1721-x","type":"journal-article","created":{"date-parts":[[2012,6,21]],"date-time":"2012-06-21T15:45:09Z","timestamp":1340293509000},"page":"8663-8667","source":"Crossref","is-referenced-by-count":12,"title":["Evaluation of the JAK2-V617F gene mutation in Turkish patients with essential thrombocythemia and polycythemia vera"],"prefix":"10.1007","volume":"39","author":[{"given":"Mutlu","family":"Karkucak","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tahsin","family":"Yakut","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vildan","family":"Ozkocaman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fahir","family":"Ozkalemkas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ridvan","family":"Ali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Murat","family":"Bayram","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Orhan","family":"Gorukmez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gokhan","family":"Ocakoglu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,6,22]]},"reference":[{"key":"1721_CR1","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1182\/blood.V6.4.372.372","volume":"6","author":"W Dameshek","year":"1951","unstructured":"Dameshek W (1951) Some speculations on the myeloproliferative syndromes. Blood 6:372\u2013375","journal-title":"Blood"},{"key":"1721_CR2","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1111\/j.1445-5994.2007.01589.x","volume":"38","author":"CH Lieu","year":"2008","unstructured":"Lieu CH, Wu HS, Hon YC et al (2008) Prevalence of the JAK2-V617F mutation in Taiwanese patients with chronic myeloproliferative disorders. Intern Med J. 38:422\u2013426","journal-title":"Intern Med J."},{"key":"1721_CR3","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1182\/blood-2002-04-1199","volume":"100","author":"JW Vardiman","year":"2002","unstructured":"Vardiman JW, Harris NL, Brunning RD (2002) The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 100:2292\u20132302","journal-title":"Blood"},{"key":"1721_CR4","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1038\/nature03546","volume":"434","author":"C James","year":"2005","unstructured":"James C, Ugo V, LeCouedic JP et al (2005) A unique clonal JAK2 mutation leading to constitutive signaling causes polycythaemia vera. Nature 434:1144\u20131148","journal-title":"Nature"},{"key":"1721_CR5","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","volume":"7","author":"RL Levine","year":"2005","unstructured":"Levine RL, Wadleigh M, Cools J et al (2005) Activating mutation of the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7:387\u2013397","journal-title":"Cancer Cell"},{"key":"1721_CR6","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1056\/NEJMoa051113","volume":"352","author":"R Kralovics","year":"2005","unstructured":"Kralovics R, Passamonti F, Buser AS et al (2005) A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352:1779\u20131790","journal-title":"N Engl J Med"},{"key":"1721_CR7","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/S0140-6736(05)74230-6","volume":"365","author":"EJ Baxter","year":"2005","unstructured":"Baxter EJ, Scott LM, Campbell PJ et al (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative diseases. Lancet 365:1054\u20131061","journal-title":"Lancet"},{"key":"1721_CR8","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.cca.2009.07.002","volume":"408","author":"TK Er","year":"2009","unstructured":"Er TK, Lin SF, Chang JG et al (2009) Detection of the JAK2 V617F missense mutation by high resolution melting analysis and its validation. Clin Chim Acta 408:39\u201344","journal-title":"Clin Chim Acta"},{"key":"1721_CR9","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.1056\/NEJMra063728","volume":"355","author":"PJ Campbell","year":"2006","unstructured":"Campbell PJ, Green AR (2006) The myeloproliferative disorders. N Engl J Med 355:2452\u20132466","journal-title":"N Engl J Med"},{"key":"1721_CR10","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1182\/blood-2005-03-1320","volume":"106","author":"AV Jones","year":"2005","unstructured":"Jones AV, Kreil S, Zoi K et al (2005) Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 106:2162\u20132168","journal-title":"Blood"},{"key":"1721_CR11","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1016\/S0140-6736(05)67785-9","volume":"366","author":"PJ Campbell","year":"2005","unstructured":"Campbell PJ, Scott LM, Buck G et al (2005) Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet 366:1945\u20131953","journal-title":"Lancet"},{"key":"1721_CR12","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1038\/sj.leu.2403902","volume":"19","author":"E Antonioli","year":"2005","unstructured":"Antonioli E, Guglielmelli P, Pancrazzi A et al (2005) Clinical implications of the JAK2 V617F mutation in essential thrombocythemia. Leukemia 19:1847\u20131849","journal-title":"Leukemia"},{"key":"1721_CR13","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1007\/s12185-010-0529-5","volume":"91","author":"M Wadleigh","year":"2010","unstructured":"Wadleigh M, Tefferi A (2010) Classification and diagnosis of myeloproliferative neoplasms according to the 2008 World Health Organization criteria. Int J Hematol 91:174\u2013179","journal-title":"Int J Hematol"},{"key":"1721_CR14","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1089\/gte.2007.0051","volume":"11","author":"V Koksal","year":"2007","unstructured":"Koksal V, Etlik O, Arican-Baris ST, Baris I (2007) A tetra-primer polymerase chain reaction approach for the detection of JAK2 V617F mutation. Genet Test 11:463\u2013466","journal-title":"Genet Test"},{"key":"1721_CR15","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s11845-007-0026-x","volume":"176","author":"SE Langabeer","year":"2007","unstructured":"Langabeer SE, Ni Ainle F, Conneally E, Lawler M (2007) Incidence and significance of the JAK2 V617F mutation in patients with chronic myeloproliferative disorders. Ir J Med Sci 176:105\u2013109","journal-title":"Ir J Med Sci"},{"key":"1721_CR16","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1177\/147323000903700105","volume":"37","author":"YM Shen","year":"2009","unstructured":"Shen YM, Chao HY, Zhang R et al (2009) Quantitative assay for Janus kinase 2 (JAK2) mutation in Chinese patients with chronic myeloproliferative disorders. J Int Med Res 37:37\u201346","journal-title":"J Int Med Res"},{"issue":"14","key":"1721_CR17","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1179\/102453309X12473408860226","volume":"2009","author":"AL Basquiera","year":"2009","unstructured":"Basquiera AL, Soria NW, Ryser R et al (2009) Clinical significance of V617F mutation of the JAK2 gene in patients with chronic myeloproliferative disorders. Hematology 2009(14):323\u2013330","journal-title":"Hematology"},{"key":"1721_CR18","doi-asserted-by":"publisher","first-page":"22788","DOI":"10.1074\/jbc.C500138200","volume":"280","author":"R Zhao","year":"2005","unstructured":"Zhao R, Xing S, Li Z, Li Q, Krantz SB, Zhao ZJ (2005) Identification of an acquired JAK2 mutation in polycythemia vera. J Biol Chem 280:22788\u201322792","journal-title":"J Biol Chem"},{"key":"1721_CR19","doi-asserted-by":"publisher","first-page":"e89","DOI":"10.1016\/j.patbio.2009.06.005","volume":"59","author":"A Benmoussa","year":"2011","unstructured":"Benmoussa A, Dehbi H, Fehri S, Quessar A, Nadifi S (2011) JAK2-V617F mutation in Moroccan patients with myeloproliferative disorders: contribution, diagnosis and therapeutic prospects. Pathol Biol. 59:e89\u2013e92","journal-title":"Pathol Biol."},{"key":"1721_CR20","first-page":"2109","volume":"87","author":"SJ Zhang","year":"2007","unstructured":"Zhang SJ, Li WD, Song JH, Xu W, Qiu HX, Li JY (2007) The investigation of JAK2 V617F point mutation in myeloproliferative disorders by allele-specific polymerase chain reaction in combination with sequence analysis. Zhonghua Yi Xue Za Zhi 87:2109\u20132112","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"1721_CR21","doi-asserted-by":"publisher","unstructured":"Wong GC, Kam GL, Koay ES (2010). JAK2 mutations in Asian patients with essential thrombocythaemia. Intern Med J. doi: 10.1111\/j.1445-5994.2010.02199.x","DOI":"10.1111\/j.1445-5994.2010.02199.x"},{"key":"1721_CR22","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1002\/cncr.21645","volume":"106","author":"A Tefferi","year":"2006","unstructured":"Tefferi A, Lasho TL, Schwager SM et al (2006) The clinical phenotype of wild-type, heterozygous, and homozygous JAK2 V617F in polycythemia vera. Cancer 106:631\u2013636","journal-title":"Cancer"},{"key":"1721_CR23","doi-asserted-by":"publisher","first-page":"3370","DOI":"10.1182\/blood-2005-05-1800","volume":"106","author":"J Jelinek","year":"2005","unstructured":"Jelinek J, Oki Y, Gharibyan V, Bueso-Ramos C, Prehal JT, Verstovsek S (2005) JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Phledelphia chromosome negative CML, and megakaryocytic leukemia. Blood 106:3370\u20133373","journal-title":"Blood"},{"key":"1721_CR24","doi-asserted-by":"publisher","first-page":"3913","DOI":"10.1182\/blood-2006-03-008805","volume":"108","author":"AR Moliterno","year":"2006","unstructured":"Moliterno AR, Donna MW, Ophelia R, Spivak JL (2006) Moleculer mimicry in the chronic myeloproliferative disorders: reciprocity between quantitative JAK2 V617F and Mpl expression. Blood 108:3913\u20133915","journal-title":"Blood"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-012-1721-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11033-012-1721-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-012-1721-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,9]],"date-time":"2020-07-09T19:21:36Z","timestamp":1594322496000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11033-012-1721-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6,22]]},"references-count":24,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["1721"],"URL":"https:\/\/doi.org\/10.1007\/s11033-012-1721-x","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,6,22]]}}}